What is the current valuation of the US Genetic Engineering Market?

As of 2024, the US Genetic Engineering Market was valued at 403.2 USD Million. Read More

What is the projected market valuation for the US Genetic Engineering Market by 2035?

The market is projected to reach a valuation of 2700.0 USD Million by 2035. Read More

What is the expected CAGR for the US Genetic Engineering Market during the forecast period 2025 - 2035?

The expected CAGR for the US Genetic Engineering Market during the forecast period 2025 - 2035 is 18.87%. Read More

Which companies are considered key players in the US Genetic Engineering Market?

Key players in the market include Monsanto, DuPont, Syngenta, Bayer, Amgen, Genentech, Illumina, Regeneron Pharmaceuticals, and Corteva Agriscience. Read More

How does the Agricultural Biotechnology segment perform in the US Genetic Engineering Market?

The Agricultural Biotechnology segment was valued at 100.0 USD Million in 2024 and is projected to grow to 600.0 USD Million by 2035. Read More

What is the valuation of the Medical Biotechnology segment in the US Genetic Engineering Market?

The Medical Biotechnology segment had a valuation of 150.0 USD Million in 2024, with projections reaching 900.0 USD Million by 2035. Read More

What are the projected values for the Industrial Biotechnology segment by 2035?

The Industrial Biotechnology segment was valued at 80.0 USD Million in 2024 and is expected to grow to 500.0 USD Million by 2035. Read More

What is the expected growth for the Environmental Biotechnology segment in the US Genetic Engineering Market?

The Environmental Biotechnology segment had a valuation of 73.2 USD Million in 2024, with projections indicating growth to 700.0 USD Million by 2035. Read More

Which technology segments are included in the US Genetic Engineering Market analysis?

The technology segments include CRISPR, Gene Therapy, Synthetic Biology, and Genetic Modification, with varying valuations from 80.0 to 113.2 USD Million in 2024. Read More

What are the research type segments in the US Genetic Engineering Market?

Research type segments include Basic Research, Applied Research, and Clinical Research, with valuations ranging from 80.0 to 173.2 USD Million in 2024. Read More

US Genome Editing Engineering Market

ID: MRFR/HC/20201-HCR

128 Pages

Nidhi Mandole

Last Updated: April 06, 2026

United States Genome Editing Engineering Market Research Report Information By Technology (Mega nucleases, Cas9, TALENs/MegaTALs, ZFN, Others), By Delivery Method (Ex-vivo, In-vivo) By Mode (Contract, In-house), By End-use (Biotechnology & Pharmaceutical Companies, Academic & Government Research Institutes, Contract Research Organizations), By Application (Genetic Engineering, Clinical Applications) – United States Market Forecast Till 2035

US Genome Editing Engineering Market Infographic

Summary Table of Contents Segmentation Download PDF

Certified Researchers

Customize Report

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Healthcare, BY Application (USD Million)
  1. 4.1.1 Agricultural Biotechnology
  2. 4.1.2 Medical Biotechnology
  3. 4.1.3 Industrial Biotechnology
  4. 4.1.4 Environmental Biotechnology
2. 4.2 Healthcare, BY End Use (USD Million)
  1. 4.2.1 Pharmaceuticals
  2. 4.2.2 Agriculture
  3. 4.2.3 Food and Beverages
  4. 4.2.4 Biofuels
3. 4.3 Healthcare, BY Technology (USD Million)
  1. 4.3.1 CRISPR
  2. 4.3.2 Gene Therapy
  3. 4.3.3 Synthetic Biology
  4. 4.3.4 Genetic Modification
4. 4.4 Healthcare, BY Research Type (USD Million)
  1. 4.4.1 Basic Research
  2. 4.4.2 Applied Research
  3. 4.4.3 Clinical Research
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Healthcare
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Monsanto (US)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 DuPont (US)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Syngenta (US)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Bayer (US)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Amgen (US)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Genentech (US)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Illumina (US)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Regeneron Pharmaceuticals (US)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 Corteva Agriscience (US)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 US MARKET ANALYSIS BY APPLICATION
3. 6.3 US MARKET ANALYSIS BY END USE
4. 6.4 US MARKET ANALYSIS BY TECHNOLOGY
5. 6.5 US MARKET ANALYSIS BY RESEARCH TYPE
6. 6.6 KEY BUYING CRITERIA OF HEALTHCARE
7. 6.7 RESEARCH PROCESS OF MRFR
8. 6.8 DRO ANALYSIS OF HEALTHCARE
9. 6.9 DRIVERS IMPACT ANALYSIS: HEALTHCARE
10. 6.10 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
11. 6.11 SUPPLY / VALUE CHAIN: HEALTHCARE
12. 6.12 HEALTHCARE, BY APPLICATION, 2024 (% SHARE)
13. 6.13 HEALTHCARE, BY APPLICATION, 2024 TO 2035 (USD Million)
14. 6.14 HEALTHCARE, BY END USE, 2024 (% SHARE)
15. 6.15 HEALTHCARE, BY END USE, 2024 TO 2035 (USD Million)
16. 6.16 HEALTHCARE, BY TECHNOLOGY, 2024 (% SHARE)
17. 6.17 HEALTHCARE, BY TECHNOLOGY, 2024 TO 2035 (USD Million)
18. 6.18 HEALTHCARE, BY RESEARCH TYPE, 2024 (% SHARE)
19. 6.19 HEALTHCARE, BY RESEARCH TYPE, 2024 TO 2035 (USD Million)
20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY APPLICATION, 2026-2035 (USD Million)
  2. 7.2.2 BY END USE, 2026-2035 (USD Million)
  3. 7.2.3 BY TECHNOLOGY, 2026-2035 (USD Million)
  4. 7.2.4 BY RESEARCH TYPE, 2026-2035 (USD Million)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

US Healthcare Market Segmentation

Healthcare By Application (USD Million, 2026-2035)

Agricultural Biotechnology
Medical Biotechnology
Industrial Biotechnology
Environmental Biotechnology

Healthcare By End Use (USD Million, 2026-2035)

Pharmaceuticals
Agriculture
Food and Beverages
Biofuels

Healthcare By Technology (USD Million, 2026-2035)

CRISPR
Gene Therapy
Synthetic Biology
Genetic Modification

Healthcare By Research Type (USD Million, 2026-2035)

Basic Research
Applied Research
Clinical Research

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”